Richard E. Pratley, MD

The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release.

SAN DIEGO — In this video exclusive, Richard Pratley, MD, discusses diabetes remission and the need for more information and clinical trials to understand the impact of remission on long-term outcomes.

SAN DIEGO — Adults with obesity and without diabetes receiving the oral GLP-1 receptor agonist orforglipron lost 8.6% to 12.6% of their body weight at 26 weeks, according to a data from a phase 2 trial.

The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.

NEW ORLEANS — In this video exclusive, Richard E. Pratley, MD, offers his picks for most exciting news to come out of the American Diabetes Association Scientific Sessions.

In this video exclusive, Richard E. Pratley, MD, talks with Deepak L. Bhatt, MD, MPH, about results and implications of the SOLOIST and SCORED trials of the SGLT1/SGLT2 inhibitor sotogliflozin vs. placebo in adults with type 2 diabetes.

In this video exclusive, Richard E. Pratley, MD, talks with Deborah J. Wexler, MD, MSc, about results and implications of the long-term GRADE study comparing the effectiveness of second-line diabetes agents in conjunction with metformin.

In this video exclusive, Richard E. Pratley, MD, the Samuel E. Crockett chair in diabetes research and medical director of AdventHealth Diabetes Institute, announces results from the AMPLITUDE-O cardiovascular outcomes study of the exendin-based GLP-1 receptor agonist efpeglenatide.

In this video exclusive, Richard E. Pratley, MD, talks with Mikhail Kosiborod, MD, FACC, FAHA, about the DARE-19 trial, which explored repurposing existing medications to treat COVID-19.